These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

990 related items for PubMed ID: 9205740

  • 21. Tolerability and pharmacokinetics of ebrotidine in healthy subjects given single and repeated oral doses.
    Farré M, Roset PN, Badenas JM, Ugena B, Márquez M, Albet C, Herrero E, Ortiz JA.
    Arzneimittelforschung; 1997 Apr; 47(4A):528-30. PubMed ID: 9205758
    [Abstract] [Full Text] [Related]

  • 22. Continuous intragastric pH monitoring in the evaluation of ebrotidine, cimetidine and placebo on gastric acidity in healthy volunteers.
    Muñoz-Navas M, Honorato J, Reina-Ariño M, Márquez M, Herrero E, Villamayor F, Torres J, Roset PN, Fíllat O, Camps F, Ortiz JA.
    Arzneimittelforschung; 1997 Apr; 47(4A):539-44. PubMed ID: 9205761
    [Abstract] [Full Text] [Related]

  • 23. Gastroprotective and ulcer-healing activities of a new H2-receptor antagonist: ebrotidine.
    Brzozowski T, Majka J, Konturek SJ.
    Digestion; 1992 Apr; 51(1):27-36. PubMed ID: 1353465
    [Abstract] [Full Text] [Related]

  • 24. Acute toxicity studies of ebrotidine.
    Grau MT, Romero A, Villamayor F, Sacristán A, Ortiz JA.
    Arzneimittelforschung; 1997 Apr; 47(4A):490-1. PubMed ID: 9205750
    [Abstract] [Full Text] [Related]

  • 25. In vitro anti-Helicobacter pylori activity of ebrotidine.
    Palacín C, Tarragó C, Sacristán A, Ortiz JA.
    Arzneimittelforschung; 1997 Apr; 47(4A):471-4. PubMed ID: 9205746
    [Abstract] [Full Text] [Related]

  • 26. Pharmacokinetics of ebrotidine in healthy volunteers. A summary.
    Albet C, Pérez JA, Rozman E, Márquez M, Herrero E, Ortiz JA.
    Arzneimittelforschung; 1997 Apr; 47(4A):535-9. PubMed ID: 9205760
    [Abstract] [Full Text] [Related]

  • 27. Pharmacology of mifentidine, a novel H2-receptor antagonist.
    Pagani F, Micheletti R, Brambilla A, Schiavone A, Montagna E, Ciprandi C, Giachetti A.
    Arzneimittelforschung; 1985 Apr; 35(1A):451-5. PubMed ID: 2859036
    [Abstract] [Full Text] [Related]

  • 28. A review of the animal pharmacology of ranitidine--a new, selective histamine H2-antagonist.
    Brittain RT, Daly MJ.
    Scand J Gastroenterol Suppl; 1981 Jun; 69():1-9. PubMed ID: 6119770
    [Abstract] [Full Text] [Related]

  • 29. Chronic toxicity of ebrotidine in rats and dogs.
    Romero A, Grau MT, Villamayor F, Sacristán A, Ortiz JA.
    Arzneimittelforschung; 1997 Apr; 47(4A):498-504. PubMed ID: 9205752
    [Abstract] [Full Text] [Related]

  • 30. Studies on MK-208 (YM-11170) a new, slowly dissociable H2-receptor antagonist.
    Pendleton RG, Torchiana ML, Chung C, Cook P, Wiese S, Clineschmidt BV.
    Arch Int Pharmacodyn Ther; 1983 Nov; 266(1):4-16. PubMed ID: 6141772
    [Abstract] [Full Text] [Related]

  • 31. Involvement of endogenous nitric oxide and sulfhydryl compounds in ebrotidine-induced gastroprotection.
    Palop D, Conejo L, Sacristán A, Ortiz JA.
    Arzneimittelforschung; 1997 Apr; 47(4A):468-71. PubMed ID: 9205745
    [Abstract] [Full Text] [Related]

  • 32. Ebrotidine versus ranitidine in the healing and prevention of relapse of duodenal ulcer. A multicentre, double-blind, parallel, randomized, controlled study.
    Tulassay Z, Döbrönte Z, Farkas I, Juhász L, Simon L, Prónai L, Torres J, Márquez M.
    Arzneimittelforschung; 1997 Apr; 47(4A):551-5. PubMed ID: 9205763
    [Abstract] [Full Text] [Related]

  • 33. Gastroprotective properties of ebrotidine. A review.
    Slomiany BL, Piotrowski J, Slomiany A.
    Arzneimittelforschung; 1997 Apr; 47(4A):459-67. PubMed ID: 9205744
    [Abstract] [Full Text] [Related]

  • 34. Carcinogenicity studies on ebrotidine.
    Romero A, Rives A, Grau MT, Villamayor F, Sacristán A, Ortiz JA.
    Arzneimittelforschung; 1997 Apr; 47(4A):515-9. PubMed ID: 9205755
    [Abstract] [Full Text] [Related]

  • 35. Characterization of the H2 receptor antagonist and gastric acid antisecretory properties of Wy-45,727.
    Nielsen ST.
    J Pharmacol Exp Ther; 1987 Aug; 242(2):607-13. PubMed ID: 2886646
    [Abstract] [Full Text] [Related]

  • 36. Kinetics and duration of action of ranitidine on gastric secretion and its effect on pancreatic secretion in duodenal ulcer patients.
    Konturek SJ, Obtułowicz W, Kwiecień N, Kopp B, Oleksy J.
    Scand J Gastroenterol Suppl; 1981 Jun; 69():91-9. PubMed ID: 6119789
    [Abstract] [Full Text] [Related]

  • 37. Ebrotidine--a new H2-receptor antagonist with mucosal strengthening activity.
    Piotrowski J, Yamaki K, Morita M, Slomiany A, Slomiany BL.
    Biochem Int; 1992 Mar; 26(4):659-67. PubMed ID: 1351724
    [Abstract] [Full Text] [Related]

  • 38. Susceptibility of Helicobacter pylori to antimicrobial agents: effect of ebrotidine and ranitidine.
    Piotrowski J, Piotrowski E, Slomiany A, Slomiany BL.
    J Physiol Pharmacol; 1995 Dec; 46(4):463-9. PubMed ID: 8770790
    [Abstract] [Full Text] [Related]

  • 39. Pharmacological comparison of ORF 17910, a potent, long-acting histamine H2-receptor antagonist, to cimetidine and ranitidine.
    Katz LB, Scott CK, Shriver DA.
    J Pharmacol Exp Ther; 1986 Aug; 238(2):587-93. PubMed ID: 2874214
    [Abstract] [Full Text] [Related]

  • 40. Study of the population of antral G-cells and enterochromaffin-like cells in the rat and mouse gastric mucosa after long-term treatment with ebrotidine.
    Romero A, Gómez F, Villamayor F, Sacristán A, Ortiz JA.
    Arzneimittelforschung; 1997 Apr; 47(4A):520-3. PubMed ID: 9205756
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 50.